Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tysabri for anti-Hu paraneoplastic neurological syndromes
NL-OMON41883Phase 2Not yet recruiting
- Sponsor
- Erasmus MC, Rotterdam
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of natalizumab in paraneoplastic neurological syndrome (PNS), paraneoplastic encephalomyelitis, paraneoplastic limbic encephalitis (PLE) and 2 more, sponsored by Erasmus MC, Rotterdam. Planned start Feb 2016; status: not yet recruiting.
02
Drugs
natalizumab
03
Conditions
paraneoplastic neurological syndrome (PNS)paraneoplastic encephalomyelitisparaneoplastic limbic encephalitis (PLE)paraneoplastic cerebellar degeneration (PCD)paraneoplastic sensory neuronopathy (PSN)
Beyond the preview
Go deeper on NL-OMON41883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41883.